The Latin America, Middle East and Africa Orthopedic Regenerative Surgical Products Market would witness market growth of 7.6% CAGR during the forecast period (2023-2030).
Sports-related injuries are frequent, and because regenerative surgical products have the potential to promote quicker recovery and better results, they are frequently used to treat them. The popularity of these therapies among athletes has also contributed to the market’s expansion. In some cases, therapies were utilized to help the healing process after surgery and to treat injuries, an area with minimal research support. In individuals suffering from degenerative joint problems and musculoskeletal traumas, regenerative medicine presents the potential of delaying and possibly minimizing surgical intervention. In coming years, orthobiologics may be employed as a therapy option for ailments like arthritis, acting as a stopgap between conservative measures (like steroid injection) and surgical intervention.
The use of regenerative surgical products to treat orthopedic disorders is becoming more widely known among patients and medical professionals, which has fuelled market growth. Numerous orthopedic regenerative surgical devices use minimally invasive techniques that decrease patient discomfort, healing time, and hospital stays. This has increased the adoption of these procedures. The adoption of orthopedic regenerative surgical devices has been positively impacted by the rise in healthcare spending.
In Latin America, there are now an increasing number of kids and teenagers who are overweight. In this region, it is thought that 3 out of 10 kids and teenagers between the ages of 5 and 19 are overweight. According to estimates from UNICEF, the World Health Organization, and the World Bank across Latin America and the Caribbean, 7.5% of children under five?or roughly 4 million?were overweight as of 2020. Obesity increases the incidence of OA not just in weight-bearing joints like the knees but also in non-weight-bearing joints like the finger joints and wrists, indicating that such metabolic mediators contribute to a rise in the incidence of osteoarthritis in obese patients. Hence, the increasing burden of obesity and overweight in this region may result in a greater prevalence of orthopedic issues, which in turn will drive the regional market.
The Brazil market dominated the LAMEA Orthopedic Regenerative Surgical Products Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $84.8 million by 2030. The Argentina market is showcasing a CAGR of 8.2% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 7.4% during (2023 - 2030).
Based on End-Use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Others. Based on Application, the market is segmented into Joint Reconstruction, Cartilage & Tendon Repair, Trauma Repair, Orthopedic Pain Management and Others. Based on Product, the market is segmented into Viscosupplements, Allografts (Amniotic Products and Others), Synthetic and Cell-based. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include MiMedx Group, Inc., Vericel Corporation, Baxter International, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, Smith & Nephew, Arthrex, Inc., BioTissue Holdings, Inc., VSY Biotechnology GmbH and Aptissen S.A.
Scope of the Study
Market Segments covered in the Report:
By End-use

  • Hospitals
  • Ambulatory Surgical Centers
  • Others


By Application

  • Joint Reconstruction
  • Cartilage & Tendon Repair
  • Trauma Repair
  • Orthopedic Pain Management
  • Others


By Product

  • Viscosupplements
  • Allografts


o Amniotic Products
o Others

  • Synthetic
  • Cell-based


By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA


Companies Profiled

  • MiMedx Group, Inc.
  • Vericel Corporation
  • Baxter International, Inc.
  • Zimmer Biomet Holdings, Inc.
  • Stryker Corporation
  • Smith & Nephew
  • Arthrex, Inc.
  • BioTissue Holdings, Inc.
  • VSY Biotechnology GmbH
  • Aptissen S.A.


Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free